We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+16.91%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$276M
AUM Growth
+$59.5M
Cap. Flow
+$34.9M
Cap. Flow %
12.66%
Top 10 Hldgs %
29.49%
Holding
157
New
25
Increased
65
Reduced
12
Closed
31

Top Buys

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$7.96M
2
HES
Hess
HES
+$4.24M
3
SOVO
Sovos Brands, Inc. Common Stock
SOVO
+$4.06M
4
SP
SP Plus Corporation
SP
+$3.96M
5
PATH icon
UiPath
PATH
+$2.41M

Top Sells

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$5.76M
2
VMW
VMware, Inc
VMW
+$5.59M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.04M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.03M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$1.53M

Sector Composition

Rank Sector Weight
1 Healthcare 45.71%
2 Technology 11.75%
3 Consumer Discretionary 6.51%
4 Industrials 5.31%
5 Consumer Staples 4.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SERA icon
126
Sera Prognostics
SERA
$77.9M
$122K 0.04%
+20,480
New +$59.5K
ACAD icon
127
Acadia Pharmaceuticals
ACAD
$5.07B
– –
-18,172
Closed -$379K
AKRO
128
DELISTED
Akero Therapeutics
AKRO
– –
-11,408
Closed -$577K
CLDX icon
129
Celldex Therapeutics
CLDX
$3.48B
– –
-17,482
Closed -$481K
CPT icon
130
Camden Property Trust
CPT
$10.9B
– –
-5,800
Closed -$549K
CZR icon
131
Caesars Entertainment
CZR
$6.06B
– –
-14,200
Closed -$658K
ETNB
132
DELISTED
89bio
ETNB
– –
-33,792
Closed -$522K
HCA icon
133
HCA Healthcare
HCA
$89.1B
– –
-2,911
Closed -$716K
HLT icon
134
Hilton Worldwide
HLT
$70.8B
– –
-4,800
Closed -$721K
INCY icon
135
Incyte
INCY
$24.5B
– –
-8,158
Closed -$471K
KRYS icon
136
Krystal Biotech
KRYS
$9.68B
– –
-4,392
Closed -$509K
NFLX icon
137
Netflix
NFLX
$311B
– –
-14,440
Closed -$545K
NTRA icon
138
Natera
NTRA
$45.1B
– –
-10,066
Closed -$445K
PANW icon
139
Palo Alto Networks
PANW
$313B
– –
-5,410
Closed -$634K
PRTA icon
140
Prothena Corp
PRTA
$473M
– –
-9,195
Closed -$444K
PTCT icon
141
PTC Therapeutics
PTCT
$6.15B
– –
-13,237
Closed -$297K
RARE icon
142
Ultragenyx Pharmaceutical
RARE
$2.66B
– –
-14,591
Closed -$520K
RXO icon
143
RXO
RXO
$3.54B
– –
-40,683
Closed -$803K
SNDX icon
144
Syndax Pharmaceuticals
SNDX
$1.81B
– –
-29,490
Closed -$428K
SRPT icon
145
Sarepta Therapeutics
SRPT
$1.92B
– –
-4,781
Closed -$580K
TKO icon
146
TKO Group
TKO
$14.2B
– –
-5,907
Closed -$497K
UBER icon
147
Uber
UBER
$160B
– –
-12,500
Closed -$575K
UNH icon
148
UnitedHealth
UNH
$365B
– –
-1,200
Closed -$605K
VERA icon
149
Vera Therapeutics
VERA
$2.17B
– –
-30,902
Closed -$424K
PRKS icon
150
United Parks & Resorts
PRKS
$2B
– –
-14,488
Closed -$670K
3 4 5
6
7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q4 2023 Portfolio in Review

As of Q4 2023, HighVista Strategies held 157 positions worth $276M, up 28% from $216M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies deployed $34.9M of net new capital in Q4 2023, opening 25 new positions and adding to 65 existing holdings. Its largest new stake was Spyre Therapeutics: 577,616 shares worth $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Micron Technology, an estimated $780K trimmed.

  • HighVista Strategies's largest Q4 2023 buy was Spyre Therapeutics: 577,616 shares worth $12.4M.
  • HighVista Strategies added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023, an estimated $2.08M increase.
  • HighVista Strategies's biggest Q4 2023 reduction was Micron Technology, cutting an estimated $780K.
  • HighVista Strategies fully exited Activision Blizzard in Q4 2023, selling an estimated $5.76M.
  • HighVista Strategies's ten largest holdings make up 29% of its $276M portfolio in Q4 2023.
  • HighVista Strategies opened 25 new positions and closed 31 in Q4 2023.
  • HighVista Strategies's portfolio value rose 28% quarter-over-quarter to $276M.

Based on HighVista Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.